RxDoctor Payments Data

Jayakrishnakamal Konijeti, MD

Nephrology · New Albany, INNPI 1295739076

Payments from drug & device makers

$2,719in general payments, 2019–2025

Across 82 payments — averaging $33.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$1K
  • AstraZeneca$325
  • Vifor Pharma, Inc.$296
  • Amgen$159
  • Novo Nordisk$125
  • OPKO Pharmaceuticals, LLC$102
  • plus $425 from 10 others

What the payments were for

  • Travel & lodging$1,05139%
  • Food & beverage$1,66261%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,719 in reported general payments places this provider in the 65th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$474,183
Medicare patients
1,087
Services billed
4,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol333$286,758
JardianceEmpagliflozin77$106,117
VelphoroSucroferric Oxyhydroxide11$36,887
JanuviaSitagliptin Phosphate14$22,960
KerendiaFinerenone32$20,313
DapagliflozinDapagliflozin Propanediol23$12,709
Hydralazine Hcl711$9,023
Febuxostat66$6,559
Calcium Acetate70$6,154
Sevelamer Carbonate43$5,763
Midodrine Hcl30$5,513
Allopurinol915$5,414
Bumetanide107$4,092
Potassium Chloride160$3,536
Cinacalcet Hcl16$3,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$325$286,758333 claims
Boehringer IngelheimJardiance$67$106,11777 claims
Fresenius USA Marketing, Inc.Velphoro$70$36,88711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 238 nephrology providers in Indiana.

Other nephrology in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →